Olaparib Pill + AZD6738
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Grade Serous Carcinoma
Conditions
High Grade Serous Carcinoma
Trial Timeline
Mar 9, 2018 → Jul 21, 2025
NCT ID
NCT03462342About Olaparib Pill + AZD6738
Olaparib Pill + AZD6738 is a phase 2 stage product being developed by AstraZeneca for High Grade Serous Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03462342. Target conditions include High Grade Serous Carcinoma.
What happened to similar drugs?
3 of 20 similar drugs in High Grade Serous Carcinoma were approved
Approved (3) Terminated (6) Active (12)
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03462342 | Phase 2 | Completed |
Competing Products
20 competing products in High Grade Serous Carcinoma